We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$146M
AUM Growth
-$58M
Cap. Flow
-$51.3M
Cap. Flow %
-35.04%
Top 10 Hldgs %
94.95%
Holding
20
New
–
Increased
4
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$1.91M
2
NSTG
NanoString Technologies, Inc.
NSTG
+$992K
3
AERI
Aerie Pharmaceuticals
AERI
+$419K
4
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
+$42.9K

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.9M
2
RGLS
Regulus Therapeutics
RGLS
+$14.1M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$6.66M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.36M
5
XLRN
Acceleron Pharma
XLRN
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 58.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$42.9M 29.35%
3,967,900
-120,000
-3% -$1.63M
UAM
2
DELISTED
Universal American Corp
UAM
$21.3M 14.59%
2,814,883
– –
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$17.2M 11.73%
975,285
+25,913
+3% +$419K
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$15M 10.26%
600,929
+70,513
+13% +$1.91M
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$12.2M 8.34%
1,191,995
– –
NSTG
6
DELISTED
NanoString Technologies, Inc.
NSTG
$9.17M 6.27%
727,857
+68,371
+10% +$992K
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
$8.6M 5.88%
1,054,864
-706,703
-40% -$6.66M
LRMR icon
8
Larimar Therapeutics
LRMR
$416M
$4.55M 3.11%
63,337
-55,186
-47% -$4.36M
NVET
9
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$4.18M 2.86%
900,155
+12,354
+1% +$42.9K
ARDX icon
10
Ardelyx
ARDX
$1.24B
$3.75M 2.56%
428,989
-39,308
-8% -$321K
OREX
11
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.33M 1.6%
542,756
-103,452
-16% -$468K
XLRN
12
DELISTED
Acceleron Pharma
XLRN
$1.66M 1.13%
48,839
-125,250
-72% -$4.07M
NDRM
13
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.35M 0.92%
83,211
-36,570
-31% -$616K
RGNX icon
14
Regenxbio
RGNX
$623M
$1.25M 0.86%
156,741
– –
BDSI
15
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$791K 0.54%
335,239
-408,156
-55% -$1.13M
RGLS
16
DELISTED
Regulus Therapeutics
RGLS
– –
-16,991
Closed -$14.1M
SCYX icon
17
SCYNEXIS
SCYX
$37M
– –
-4,215
Closed -$1.36M
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-264,583
Closed -$16.9M
BDSI
19
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-209,500
Closed -$943K
ANAC
20
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-31,000
Closed -$2M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q2 2016 Portfolio in Review

As of Q2 2016, Foresite Capital Management II held 20 positions worth $146M, down 28% from $204M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Foresite Capital Management II withdrew a net $51.3M in Q2 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $16.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 66% a quarter earlier.

Against the trend, Foresite Capital Management II added an estimated $1.91M to Alder Biopharmaceuticals.

  • Foresite Capital Management II added most to Alder Biopharmaceuticals in Q2 2016, an estimated $1.91M increase.
  • Foresite Capital Management II's biggest Q2 2016 reduction was Adaptimmune Therapeutics, cutting an estimated $6.66M.
  • Foresite Capital Management II fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2016, selling an estimated $16.9M.
  • Foresite Capital Management II's ten largest holdings make up 95% of its $146M portfolio in Q2 2016.
  • Foresite Capital Management II opened 0 new positions and closed 5 in Q2 2016.
  • Foresite Capital Management II's portfolio value fell 28% quarter-over-quarter to $146M.

Based on Foresite Capital Management II's 13F filing for Q2 2016, filed 12 Aug 2016.